17 Apr Sanofi and GlaxoSmithKline Join Forces to Develop a Coronavirus Vaccine
GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY), two European pharmaceutical companies that are leaders in vaccines for viral diseases, announced a collaboration to develop an adjuvanted vaccine for SARS-CoV-2, the coronavirus that causes COVID-19. If the vaccine succeeds in clinical trials scheduled to start later this year, it could be available in the second half of 2021.